As of 2025-03-22, the EV/EBITDA ratio of Fulcrum Therapeutics Inc (FULC) is -18.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FULC's latest enterprise value is 111.82 mil USD. FULC's TTM EBITDA according to its financial statements is -6.07 mil USD. Dividing these 2 quantities gives us the above FULC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 9.5x | 8.4x |
| Forward P/E multiples | 9.4x - 17.0x | 12.8x |
| Fair Price | 0.03 - 0.01 | (0.12) |
| Upside | -99.2% - -99.7% | -103.8% |
| Date | EV/EBITDA |
| 2025-03-19 | -16.82 |
| 2025-03-18 | -17.27 |
| 2025-03-17 | -18.16 |
| 2025-03-14 | -18.16 |
| 2025-03-13 | -16.20 |
| 2025-03-12 | -17.36 |
| 2025-03-11 | -16.74 |
| 2025-03-10 | -16.82 |
| 2025-03-07 | -18.34 |
| 2025-03-06 | -19.05 |
| 2025-03-05 | -19.32 |
| 2025-03-04 | -19.49 |
| 2025-03-03 | -19.23 |
| 2025-02-28 | -22.34 |
| 2025-02-27 | -20.38 |
| 2025-02-26 | -19.94 |
| 2025-02-25 | -23.32 |
| 2025-02-24 | -23.32 |
| 2025-02-21 | -24.65 |
| 2025-02-20 | -24.65 |
| 2025-02-19 | -24.56 |
| 2025-02-18 | -23.94 |
| 2025-02-14 | -23.23 |
| 2025-02-13 | -23.41 |
| 2025-02-12 | -22.07 |
| 2025-02-11 | -21.00 |
| 2025-02-10 | -22.69 |
| 2025-02-07 | -23.23 |
| 2025-02-06 | -24.47 |
| 2025-02-05 | -25.19 |
| 2025-02-04 | -24.38 |
| 2025-02-03 | -24.30 |
| 2025-01-31 | -25.63 |
| 2025-01-30 | -27.59 |
| 2025-01-29 | -26.70 |
| 2025-01-28 | -26.43 |
| 2025-01-27 | -26.88 |
| 2025-01-24 | -27.41 |
| 2025-01-23 | -27.23 |
| 2025-01-22 | -26.79 |
| 2025-01-21 | -25.99 |
| 2025-01-17 | -25.63 |
| 2025-01-16 | -25.81 |
| 2025-01-15 | -26.88 |
| 2025-01-14 | -26.52 |
| 2025-01-13 | -27.50 |
| 2025-01-10 | -29.28 |
| 2025-01-08 | -30.26 |
| 2025-01-07 | -33.90 |
| 2025-01-06 | -34.17 |